guest ::
| Home > Publications Database > Progressive supranuclear palsy. > print |
| Home > Publications Database > Progressive supranuclear palsy. > print |
| 001 | 144973 | ||
| 005 | 20240813150347.0 | ||
| 024 | 7 | _ | |a 10.1016/bs.irn.2019.10.013 |2 doi |
| 024 | 7 | _ | |a pmid:31779824 |2 pmid |
| 024 | 7 | _ | |a 0074-7742 |2 ISSN |
| 024 | 7 | _ | |a 2162-5514 |2 ISSN |
| 024 | 7 | _ | |a altmetric:71416658 |2 altmetric |
| 037 | _ | _ | |a DZNE-2020-00337 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Giagkou, Nikolaos |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Progressive supranuclear palsy. |
| 260 | _ | _ | |a Heidelberg [u.a.] |c 2019 |b Elsevier, Acad. Press |
| 264 | _ | 1 | |3 print |2 Crossref |b Elsevier |c 2019-01-01 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1723554197_24566 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Progressive supranuclear palsy (PSP) is a neurodegenerative disease characterized pathologically by 4 repeat tau deposition in various cell types and anatomical regions. Richardson's syndrome (RS) is the initially described and one of the clinical phenotypes associated with PSP pathology, characterized by vertical supranuclear gaze paly in particular downwards, postural instability with early falls and subcortical frontal dementia. PSP can manifest as several other clinical phenotypes, including PSP-parkinsonism, -pure akinesia with gait freezing, -frontotemporal dementia, - corticobasal syndrome, - speech/language impairment. RS can also have a pathologic diagnosis other than PSP, including corticobasal degeneration, FTD-TDP-43 and others. New clinical diagnostic criteria take into account this phenotypic variability in an attempt to diagnose the disease earlier, given the current lack of a validated biomarker. At present, therapeutic options for PSP are symptomatic and insufficient. Recent large neuroprotective trials have failed to provide a positive clinical outcome, however, have led to the design of better studies that are ongoing and hold promise for a neuroprotective treatment for PSP. |
| 536 | _ | _ | |a 344 - Clinical and Health Care Research (POF3-344) |0 G:(DE-HGF)POF3-344 |c POF3-344 |f POF III |x 0 |
| 542 | _ | _ | |i 2019-01-01 |2 Crossref |u https://www.elsevier.com/tdm/userlicense/1.0/ |
| 588 | _ | _ | |a Dataset connected to CrossRef Book Series, PubMed, |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Supranuclear Palsy, Progressive: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Supranuclear Palsy, Progressive: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Supranuclear Palsy, Progressive: metabolism |2 MeSH |
| 650 | _ | 2 | |a Supranuclear Palsy, Progressive: physiopathology |2 MeSH |
| 700 | 1 | _ | |a Höglinger, Günter U |0 P:(DE-2719)2811373 |b 1 |u dzne |
| 700 | 1 | _ | |a Stamelou, Maria |0 P:(DE-HGF)0 |b 2 |e Corresponding author |
| 773 | 1 | 8 | |a 10.1016/bs.irn.2019.10.013 |b : Elsevier, 2019-01-01 |p 49-86 |3 book-chapter |2 Crossref |t International Review of Neurobiology |y 2019 |x 0074-7742 |
| 773 | _ | _ | |a 10.1016/bs.irn.2019.10.013 |0 PERI:(DE-600)209876-3 |p 49-86 |t International review of neurobiology |v 149 |y 2019 |x 0074-7742 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/144973/files/DZNE-2020-00337_Restricted.pdf |
| 856 | 4 | _ | |u https://pub.dzne.de/record/144973/files/DZNE-2020-00337_Restricted.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |p VDB |o oai:pub.dzne.de:144973 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 1 |6 P:(DE-2719)2811373 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-344 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2019 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1120 |2 StatID |b BIOSIS Reviews Reports And Meetings |
| 920 | 1 | _ | |0 I:(DE-2719)1110002 |k AG Höglinger 1 ; AG Höglinger |l Translational Neurodegeneration |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1110002 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|